05.07 2017

Charles Rosier - London, UK

Image Charles Rosier - London, UK

A Glimpse at Charles Rosier’s Life

Charles Rosier (charlesrosier) studied at Fenelon Sainte-Marie and received his scientific degree in the year 1991. To prepare himself for ESCP Europe, he took additional classes at a private school called Integrale. In 1996, Charles Rosier startedhis job at Lehman Brothers before later joining UBS Warburg Investment Bank. He then became the head of the finance department at Goldman Sachs Bank. He switched jobs several times while pursuing his career in the market as an investment banker.

How He Built up His Successful Career

In the year 1999, Charles Rosier was offered a job at Goldman Sachs (GMS). When he accepted the offer, he became their Managing Director. Charles Rosier’s very first appointment was at Lehman Brothers in the year 1996. At some point, he became the manager of their Debt Capital Market Division, having moved to UBS Warburg in the year 1997. He is popular as being one of the most seasoned bankers in over 15 years.

Charles Rosier's Programmes on Environmental Awareness

Charles Rosier gave his support to Luci MPOWERD, being the perfect source of clean and renewable-energy. Charles Rosier helped the company to produce more innovative solutions. He funded MPOWERD to formulate other energy solutions such as lanterns. As a result, over 25 poor countries all over the world have been supplied by MPOWERD. Charles Rosier is a partner at Innoveox, a French organisation working on fostering a friendly and pollution-free environment.

Health-Related Projects

Charles Rosier was the primary investor of the project, for which a drug was being tested to cure stroke that causes damage to the spinal cord. As an investor, Charles Rosier gets a profit-share from the company because of his contribution that enabled the company to begin doing the research. He also invested capital in the laboratory of Mapreg, situated in Paris, to continue doing research about serious issues including depression and stroke. Baulieu and his co-workers were developing a new useful drug, however they needed more funds to develop such a drug... so he invested in them.